Home News Page 66

News

Preclinical Data Shows c-Met to be a Potential Target for Antibody-drug Conjugates

Preclinical data on Sorrento Therapeutics' bi-specific antibodies (BsAbs; also known as “dual specificity” antibodies) and antibody drug conjugates (ADCs) against c-Met...

Daniel Kazado Elected as New Chairman of the Board of Immune Pharmaceuticals

This month Immune Pharmaceuticals Inc., which applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to...

Novel CD33-targeting Antibody-drug Conjugate IMGN779 Is Highly Active In Vitro and In Vivo Against...

Acute myeloid leukemia (AML), the most common type of acute leukemia in adults which is also known as acute...

IMGN529 Achieves Objective Responses in 40% of Evaluable Patients with Heavily Pretreated Diffuse Large...

Results from a clinical trial with IMGN529, ImmunoGen's experimental therapy for B-cell malignancies presented at the American Society of...

Payload Selection for Antibody-drug Conjugates

Antibody-drug conjugates or  are an emerging area of study within medicinal chemistry research. Due to their specificity to disease-targeted...

Company Files Novel Antibody-Drug Conjugate Patent Application

Earlier this year, Woonsocket, Rhode Island, based MultiCell Technologies, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for...

Polatuzumab Vedotin and Pinatuzumab Vedotin + Rituximab Generally Well-tolerated With Similar Toxicity Profiles

Updated data on the investigational antibody-drugs conjugates polatuzumab vedotin (anti-CD79b; DCDS4501A) and pinatuzumab vedotin (anti-CD22; DCDT2980S) were presented during...

SGN-CD33A Demonstrates Encouraging Antitumor Activity in Acute Myeloid Leukemia

To-date, the treatment of acute myeloid leukemia or  AML remains general unsatisfactory.  Both the medical and scientific communities are...

Brentuximab Vedotin in Frontline and Salvage Hodgkin Lymphoma

Multiple presentations at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA,...

Four-Year Survival Data from Brentuximab Vedotin Trial in Relapsed or Refractory Systemic Anaplastic Large...

Four-year overall survival (OS) data from the brentuximab vedotin (Adcetris®; Seattle Genetics) pivotal Phase II clinical trial in relapsed or...